{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:36:05Z","timestamp":1791408965507,"version":"4.3.3"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.cllc.2013.04.013","type":"journal-article","created":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T05:15:55Z","timestamp":1372310155000},"page":"558-567.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["ERCC1, MLH1, MSH2, MSH6, and \u03b2III-Tubulin: Resistance Proteins Associated With\u00a0Response and Outcome to Platinum-based Chemotherapy in Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"14","author":[{"given":"Saskia","family":"Ting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian D.","family":"Mairinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Welter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried E.","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremias","family":"Wohlschlaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt W.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2013.04.013_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.bjc.6600673","article-title":"Chemotherapy for malignant pleural mesothelioma: past results and recent developments","volume":"88","author":"Tomek","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2013.04.013_bib2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(04)17108-0","article-title":"Pleural mesothelioma: little evidence, still time to do trials","volume":"364","author":"Treasure","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2013.04.013_bib3","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2013.04.013_bib4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.cllc.2013.04.013_bib5","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2013.04.013_bib6","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials","volume":"99","author":"Ceresoli","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2013.04.013_bib7","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"Zucali","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2013.04.013_bib8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/1078-0432.CCR-09-2204","article-title":"MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer","volume":"16","author":"Kamal","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2013.04.013_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.lungcan.2011.04.014","article-title":"Chemotherapy and targeted therapies for unresectable malignant mesothelioma","volume":"73","author":"Kelly","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2013.04.013_bib10","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.lungcan.2004.04.020","article-title":"Chemotherapy for malignant pleural mesothelioma: past results and recent developments","volume":"45","author":"Tomek","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2013.04.013_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CLC.2003.n.004","article-title":"Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine\/cisplatin-treated advanced non-small-cell lung cancer patients","volume":"4","author":"Camps","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2013.04.013_bib12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MCP.0b013e32816b5c63","article-title":"ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer","volume":"13","author":"Olaussen","year":"2007","journal-title":"Curr Opin Pul Med"},{"key":"10.1016\/j.cllc.2013.04.013_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/107327480301000404","article-title":"Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer","volume":"10","author":"Rosell","year":"2003","journal-title":"Cancer Control"},{"key":"10.1016\/j.cllc.2013.04.013_bib14","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JTO.0b013e318155a637","article-title":"ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer","volume":"2","author":"Booton","year":"2007","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2013.04.013_bib15","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-11-0790","article-title":"Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC","volume":"17","author":"Friboulet","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2013.04.013_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.lungcan.2007.08.025","article-title":"ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer","volume":"59","author":"Fujii","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2013.04.013_bib17","doi-asserted-by":"crossref","first-page":"e25164","DOI":"10.1371\/journal.pone.0025164","article-title":"Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations","volume":"6","author":"Hubner","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2013.04.013_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/JTO.0b013e318233d6a9","article-title":"Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival","volume":"7","author":"Zimling","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2013.04.013_bib19","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/0008-5472.CAN-09-1237","article-title":"Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue","volume":"69","author":"Bhagwat","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2013.04.013_bib20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2559.2011.03854.x","article-title":"Personalized medicine for lung cancer: new challenges for pathology","volume":"60","author":"Kerr","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.cllc.2013.04.013_bib21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2013.04.013_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.gde.2008.01.016","article-title":"DNA repair deficiency as a therapeutic target in cancer","volume":"18","author":"Martin","year":"2008","journal-title":"Curr Opin Genet Div"},{"key":"10.1016\/j.cllc.2013.04.013_bib23","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2006.09.7915","article-title":"Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer","volume":"25","author":"Cobo","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2013.04.013_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/emmm.200900040","article-title":"Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2","volume":"1","author":"Martin","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cllc.2013.04.013_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ccr.2009.12.046","article-title":"DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1","volume":"17","author":"Martin","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cllc.2013.04.013_bib26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.lungcan.2010.10.009","article-title":"Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers","volume":"72","author":"Lo","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2013.04.013_bib27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.lungcan.2008.09.018","article-title":"Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas","volume":"64","author":"Vageli","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2013.04.013_bib28","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1349-7006.2010.01699.x","article-title":"Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer","volume":"101","author":"Kim","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2013.04.013_bib29","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1158\/1078-0432.CCR-04-0247","article-title":"Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy","volume":"10","author":"Zhou","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2013.04.013_bib30","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdh319","article-title":"Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer","volume":"15","author":"Isla","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2013.04.013_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jss.2009.09.006","article-title":"Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer","volume":"168","author":"Okuda","year":"2011","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.cllc.2013.04.013_bib32","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2174\/156652411798062368","article-title":"Class III \u00df-tubulin (TUBB3): more than a biomarker in solid tumors?","volume":"11","author":"Mariani","year":"2011","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.cllc.2013.04.013_bib33","doi-asserted-by":"crossref","first-page":"9356","DOI":"10.1158\/0008-5472.CAN-07-0509","article-title":"Class III beta-tubulin mediates sensitivity to\u00a0chemotherapeutic drugs in non small cell lung cancer","volume":"67","author":"Gan","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2013.04.013_bib34","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1158\/0008-5472.CAN-09-4487","article-title":"betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer","volume":"70","author":"McCarroll","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2013.04.013_bib35","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy","volume":"28","author":"Righi","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2013.04.013_bib36","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","article-title":"A\u00a0proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group","volume":"108","author":"Rusch","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.cllc.2013.04.013_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2013.04.013_bib38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2007.07.012","article-title":"Assessment of tumor response in malignant pleural mesothelioma","volume":"33","author":"Ceresoli","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cllc.2013.04.013_bib39","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/JTO.0b013e318260deaa","article-title":"Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma","volume":"7","author":"Christoph","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2013.04.013_bib40","first-page":"2203","article-title":"Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis","volume":"124","author":"Chao","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cllc.2013.04.013_bib41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/annonc\/mdr033","article-title":"Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials","volume":"23","author":"Reiman","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2013.04.013_bib42","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMc070742","article-title":"ERCC1 and non-small-cell lung cancer","volume":"356","author":"Niedernhofer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2013.04.013_bib43","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMc072007","article-title":"ERCC1-specific immunostaining in non-small-cell lung cancer","volume":"357","author":"Olaussen","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2013.04.013_bib44","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730413000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730413000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:04:24Z","timestamp":1761505464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730413000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1525730413000818"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2013.04.013","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ERCC1, MLH1, MSH2, MSH6, and \u03b2III-Tubulin: Resistance Proteins Associated With\u00a0Response and Outcome to Platinum-based Chemotherapy in Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2013.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}